Cover Image

Cover Image

Endothelial cells in 2-dimensional tissue culture are able to migrate (indicated by arrows), proliferate, and form chordlike structure. When placed in 3-dimensional culture in a collagen matrix, endothelial cells form tunnels and generate a lumen, thereby displaying properties that are considered essential for assembling the vasculature in vivo. Sacharidou and colleagues have identified a signaling complex, termed “endothelial lumen signaling complex,” which is required for tunnel and lumen formation in 3-dimensional culture of endothelial cells in collagen matrix, but not for cell migration in 2-dimensional tissue culture. Professional illustration by Marie Dauenheimer. See the commentary by Blobel on page 5128.
Front Matter
Table of Contents
Back Matter
Advertising
Editorial Board

All Issues

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Cardiac complete response in AL amyloidosis has similar survival to matched general population

Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma

Heme induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice

Interleukin-1 mediated hyperinflammation in XIAP-deficiency is associated with defective autophagy.

NOVEL THERAPEUTIC APPROACHES IN THALASSEMIAS, SICKLE CELL DISEASE AND OTHER RED CELL DISORDERS

Table of Contents

INSIDE BLOOD

Somatic ALPS: a FAScinating condition

HLA-DR meets ERK

Making a better antibody: all is not lost

3D trumps 2D when studying endothelial cells

PERSPECTIVES

G-CSF and its receptor in myeloid malignancy

CLINICAL TRIALS AND OBSERVATIONS

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
CME

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
Clinical Trials & Observations

GENE THERAPY

Coexpression of the T-cell receptor constant α domain triggers tumor reactivity of single-chain TCR-transduced human T cells

IMMUNOBIOLOGY

Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome

Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection

LYMPHOID NEOPLASIA

Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Pegylated arginase I: a potential therapeutic approach in T-ALL

MYELOID NEOPLASIA

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

THROMBOSIS AND HEMOSTASIS

Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation

TRANSPLANTATION

Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses

VASCULAR BIOLOGY

Endothelial lumen signaling complexes control 3D matrix–specific tubulogenesis through interdependent Cdc42- and MT1-MMP–mediated events

LYL1 activity is required for the maturation of newly formed blood vessels in adulthood

OTHER DEPARTMENTS

Continuing Medical Education (CME) questions: Treatment of acute promyelocytic leukemia based on 2 regimens (LPA99- ATRA + idarubicin -AIDA and LPA2005-risk adjusted)
CME

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

INSIDE BLOOD

PERSPECTIVES

CLINICAL TRIALS AND OBSERVATIONS

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome CME

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning Clinical Trials & Observations

GENE THERAPY

IMMUNOBIOLOGY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

VASCULAR BIOLOGY

OTHER DEPARTMENTS

Continuing Medical Education (CME) questions: Treatment of acute promyelocytic leukemia based on 2 regimens (LPA99- ATRA + idarubicin -AIDA and LPA2005-risk adjusted) CME

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
CME

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
Clinical Trials & Observations

Continuing Medical Education (CME) questions: Treatment of acute promyelocytic leukemia based on 2 regimens (LPA99- ATRA + idarubicin -AIDA and LPA2005-risk adjusted)
CME